Assessing the social value of novel regimens for MDR TB


Baltimore, Maryland, US


07/01/2014 - 06/01/2015


David Dowdy, MD, PhD, ScM

We are collaborating with investigators from the Berman Bioethics Institute to develop novel techniques for economic evaluation that also incorporate considerations of social value, using novel regimens for MDR-TB as a paradigmatic example.


MDR TB treatment as prevention: modeling the...

We are using transmission modeling to evaluate the potential impact of expanding DST and access to MDR TB treatment in Vietnam,...

Read More

Quantiferon gold test for detecting TB...

This is a cluster randomized trial comparing the time to known latent TB status among HIV infected patients receiving QGIT...

Read More

The role of cell wall lipids in pathogenesis...

This study will use a combination of transcriptional, lipidomic, genetic, and imaging techniques to investigate whether...

Read More

ACTG trial A5343

Phase 2 safety study of bedaquiline and delamanid for the treatment of MDR-TB in South Africa

Read More